Radiopharm Theranostics (RADX) Competitors $6.20 +0.14 (+2.31%) As of 10/3/2025 03:55 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsOwnershipSEC FilingsShort InterestTrendsBuy This Stock RADX vs. FBRX, BDTX, CHRS, GNFT, PRE, MXCT, CCCC, SLS, SGMO, and MCRBShould you be buying Radiopharm Theranostics stock or one of its competitors? The main competitors of Radiopharm Theranostics include Forte Biosciences (FBRX), Black Diamond Therapeutics (BDTX), Coherus Oncology (CHRS), GENFIT (GNFT), Prenetics Global (PRE), MaxCyte (MXCT), C4 Therapeutics (CCCC), SELLAS Life Sciences Group (SLS), Sangamo Therapeutics (SGMO), and Seres Therapeutics (MCRB). These companies are all part of the "med - biomed/gene" industry. Radiopharm Theranostics vs. Its Competitors Forte Biosciences Black Diamond Therapeutics Coherus Oncology GENFIT Prenetics Global MaxCyte C4 Therapeutics SELLAS Life Sciences Group Sangamo Therapeutics Seres Therapeutics Forte Biosciences (NASDAQ:FBRX) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations. Is FBRX or RADX more profitable? Radiopharm Theranostics' return on equity of 0.00% beat Forte Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Forte BiosciencesN/A -85.38% -72.34% Radiopharm Theranostics N/A N/A N/A Does the media favor FBRX or RADX? In the previous week, Forte Biosciences had 1 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 3 mentions for Forte Biosciences and 2 mentions for Radiopharm Theranostics. Forte Biosciences' average media sentiment score of 0.85 beat Radiopharm Theranostics' score of 0.00 indicating that Forte Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forte Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Radiopharm Theranostics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation & earnings, FBRX or RADX? Radiopharm Theranostics has higher revenue and earnings than Forte Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioForte BiosciencesN/AN/A-$35.48M-$16.29-0.95Radiopharm Theranostics$2.35M20.79N/AN/AN/A Do institutionals & insiders believe in FBRX or RADX? 77.6% of Forte Biosciences shares are owned by institutional investors. 5.9% of Forte Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts prefer FBRX or RADX? Forte Biosciences presently has a consensus price target of $68.00, indicating a potential upside of 338.99%. Radiopharm Theranostics has a consensus price target of $15.00, indicating a potential upside of 141.94%. Given Forte Biosciences' higher probable upside, research analysts clearly believe Forte Biosciences is more favorable than Radiopharm Theranostics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Forte Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Radiopharm Theranostics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.00 SummaryForte Biosciences beats Radiopharm Theranostics on 6 of the 11 factors compared between the two stocks. Get Radiopharm Theranostics News Delivered to You Automatically Sign up to receive the latest news and ratings for RADX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RADX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RADX vs. The Competition Export to ExcelMetricRadiopharm TheranosticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.77M$3.31B$6.05B$10.58BDividend YieldN/A2.27%5.68%4.69%P/E RatioN/A21.7377.3326.67Price / Sales20.79458.48606.38133.73Price / CashN/A46.6137.7361.25Price / BookN/A9.9312.556.55Net IncomeN/A-$52.59M$3.30B$277.26M7 Day Performance7.83%5.22%28,056.13%2.37%1 Month Performance10.71%13.01%28,993.65%9.30%1 Year PerformanceN/A25.19%35,460.84%30.78% Radiopharm Theranostics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RADXRadiopharm TheranosticsN/A$6.20+2.3%$15.00+141.9%N/A$47.77M$2.35M0.00N/APositive NewsFBRXForte Biosciences3.1088 of 5 stars$14.25-5.0%$68.00+377.2%+209.8%$186.49MN/A-0.875Options VolumeHigh Trading VolumeBDTXBlack Diamond Therapeutics3.5046 of 5 stars$3.11-4.6%$11.00+253.7%+6.3%$185.61MN/A13.5290Positive NewsCHRSCoherus Oncology4.2134 of 5 stars$1.45-8.2%$4.51+211.2%+57.7%$183.64M$266.96M0.94330News CoverageGNFTGENFIT1.435 of 5 stars$3.53-2.8%$7.00+98.3%-24.5%$181.51M$76.77M0.00120Gap UpHigh Trading VolumePREPrenetics Global0.9854 of 5 stars$12.31-10.1%$9.00-26.9%+233.4%$177.89M$30.62M-3.091Upcoming EarningsShort Interest ↓MXCTMaxCyte2.9342 of 5 stars$1.53-7.8%$7.00+357.5%-52.8%$176.97M$38.63M-3.5680News CoverageGap UpCCCCC4 Therapeutics3.7227 of 5 stars$2.19-9.5%$8.50+288.1%-57.5%$172.23M$35.58M-1.39150Gap UpSLSSELLAS Life Sciences Group2.2872 of 5 stars$1.61-1.2%$7.00+334.8%+50.8%$171.63M$1M-5.0310News CoverageShort Interest ↓SGMOSangamo Therapeutics2.1074 of 5 stars$0.63+12.1%$4.50+610.7%-13.8%$170.44M$57.80M-2.18480High Trading VolumeMCRBSeres Therapeutics2.4733 of 5 stars$18.90-2.5%$14.33-24.2%+23.0%$169.75M$126.32M-4.11330Positive News Related Companies and Tools Related Companies FBRX Competitors BDTX Competitors CHRS Competitors GNFT Competitors PRE Competitors MXCT Competitors CCCC Competitors SLS Competitors SGMO Competitors MCRB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RADX) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated b...Banyan Hill Publishing | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | SponsoredTilson: “I’m watching HOOD”A strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Radiopharm Theranostics Limited - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Radiopharm Theranostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
